Caribou Biosciences (CRBU) Long-Term Debt Issuances (2020)
Caribou Biosciences (CRBU) reported Long-Term Debt Issuances of $4000.0 for Q4 2020, little changed on a QoQ basis from $4000.0 in Q3 2020.
Caribou Biosciences (CRBU) has 1 years of Long-Term Debt Issuances data on file, last reported at $4000.0 in Q4 2020.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to $4000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2021 was $8000.0 (changed N/A YoY) and the FY2020 annual result came in at $1.6 million, changed N/A from the prior year.
- Long-Term Debt Issuances steadied at $4000.0 in Q4 2020 per CRBU's latest filing, from $4000.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $4000.0 in Q3 2020 and bottomed at $4000.0 in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 4,000.00 |
| Dec 31, 2020 | 4,000.00 |
| Sep 30, 2020 | 4,000.00 |
| Sep 30, 2020 | 4,000.00 |